
Luminex Corporation Financial Statements 2011-2026 | LMNX
Annual Financial Statements Luminex Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.27 B | 1.02 B | 1.21 B | 868 M | 832 M | 808 M | 733 M | 759 M | 742 M | 818 M |
Shares |
45.1 M | 44.1 M | 43.7 M | 43.2 M | 42.6 M | 42.1 M | 41.6 M | 40.8 M | 40.9 M | 41.3 M |
Net Income |
15.2 M | -3.84 M | 18.5 M | 29.4 M | 13.8 M | 36.9 M | 39 M | 7.1 M | 12.4 M | 14.5 M |
Revenue |
417 M | 335 M | 316 M | 307 M | 271 M | 238 M | 227 M | 213 M | 203 M | 184 M |
EBITDA |
72.9 M | -672 K | 36.5 M | 46 M | 31.5 M | 41.3 M | 33.9 M | 11.3 M | 27 M | 27.2 M |
Operating Expenses |
205 M | 195 M | 168 M | 162 M | 156 M | 131 M | 130 M | 136 M | 120 M | 102 M |
General and Administrative Expenses |
140 M | 127 M | 112 M | 107 M | 99.5 M | 84.8 M | 82.8 M | 87.3 M | 74.8 M | 64.9 M |
All numbers in USD currency
Main types of financial statements Luminex Corporation LMNXFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Luminex Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Baxter International
BAX
|
$ 19.11 | -0.98 % | $ 9.75 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 194.07 | -0.8 % | $ 55.8 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.64 | -18.34 % | $ 174 M | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.67 | 1.66 % | $ 28.4 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Repro Med Systems
KRMD
|
$ 5.81 | 2.11 % | $ 265 M | ||
|
Alcon
ALC
|
$ 78.81 | -0.64 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 39.56 | -1.54 % | $ 1.86 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
ICU Medical
ICUI
|
$ 142.67 | -1.36 % | $ 3.48 B | ||
|
electroCore
ECOR
|
$ 4.49 | -3.55 % | $ 24.8 K | ||
|
iRhythm Technologies
IRTC
|
$ 177.44 | -0.63 % | $ 5.54 B | ||
|
AngioDynamics
ANGO
|
$ 12.84 | -1.23 % | $ 525 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
$ 81.96 | -0.62 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
$ 112.91 | -1.16 % | $ 5.47 B | ||
|
LeMaitre Vascular
LMAT
|
$ 81.1 | -2.3 % | $ 1.82 B | ||
|
Haemonetics Corporation
HAE
|
$ 80.15 | -1.02 % | $ 4.03 B | ||
|
InfuSystem Holdings
INFU
|
$ 8.97 | 0.67 % | $ 185 M | ||
|
Masimo Corporation
MASI
|
$ 130.06 | -0.77 % | $ 6.93 B | ||
|
OraSure Technologies
OSUR
|
$ 2.42 | -2.02 % | $ 180 M | ||
|
Merit Medical Systems
MMSI
|
$ 88.14 | -0.47 % | $ 5.13 B | ||
|
Intuitive Surgical
ISRG
|
$ 566.36 | -1.09 % | $ 201 B | ||
|
Microbot Medical
MBOT
|
$ 2.0 | -2.44 % | $ 20.4 M | ||
|
Milestone Scientific
MLSS
|
$ 0.27 | -0.22 % | $ 21.5 M | ||
|
Nephros
NEPH
|
$ 4.88 | 3.39 % | $ 50.7 M | ||
|
Stereotaxis
STXS
|
$ 2.3 | -0.22 % | $ 186 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
$ 21.71 | -0.91 % | $ 3.74 B | ||
|
STERIS plc
STE
|
$ 253.52 | -0.76 % | $ 25 B | ||
|
Pro-Dex
PDEX
|
$ 38.48 | -0.3 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Utah Medical Products
UTMD
|
$ 55.96 | -0.57 % | $ 203 M | ||
|
Pulse Biosciences
PLSE
|
$ 13.73 | 0.22 % | $ 660 M | ||
|
ResMed
RMD
|
$ 240.87 | -0.91 % | $ 35.2 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.43 | 0.35 % | $ 2.32 B | ||
|
Repligen Corporation
RGEN
|
$ 163.86 | -1.64 % | $ 9.13 M | ||
|
BioLife Solutions
BLFS
|
$ 24.18 | -1.95 % | $ 1.11 B | ||
|
Retractable Technologies
RVP
|
$ 0.77 | -0.63 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
$ 23.09 | -0.52 % | $ 1.13 B | ||
|
Teleflex Incorporated
TFX
|
$ 122.04 | 0.35 % | $ 5.72 B | ||
|
West Pharmaceutical Services
WST
|
$ 275.14 | -0.62 % | $ 20.1 B |